日前，海思科（002653）向特定对象发行股票的申请获得深圳证券交易所上市审核中心审核通过。 图/海思科定增申请获深交所上市审核中心通过 海思科本次向特定对象发行股票数量不超过7000万股，未超过本次发行前总股本的30%。公司本次向特定对象发行股票募集资金总额不超过124,525.67万 元，募集资金扣除相关发行费用后将用于新药研发项目、补充流动资金。 | | | | 早位: | | --- | --- | --- | --- | | 序号 | 项目名称 | 项目投资金额 | 拟使用募集资金金额 | | | 新约研发项目 | 96,525.67 | 96.525.67 | | 2 | 补充流动货金 | 28.000.00 | 28.000.00 | | | 合计 | 124.525.67 | 124.525.67 | 图/海思科定增募投项目 值得指出的是，公司当前正处于向创新药转型的关键时期，研发投入保持较高强度，2022年至2024年公司研发支出占当期营收的比例分别达到31.87%、 26.09%和26.90%，而研发管线的收获亦日益转换为公司业绩可持续增长的基石。 特别地，近年来海思科重磅产品市场份额持续 ...

Core Viewpoint - Tianjin Pharmaceutical Industry is undergoing a strategic transformation from a "production-driven" model to a "dual empowerment of R&D and market" approach, as indicated by the company's recent organizational changes and focus on core business areas [2][3]. Group 1: Organizational Changes - In September 2023, Tianjin Pharmaceutical established two main centers for raw material manufacturing and sales, with additional centers for product planning and R&D set to launch in early 2024 [2]. - The company aims to optimize its organizational structure to adapt to new industry dynamics, reflecting a comprehensive strategic choice beyond merely rebranding [2]. Group 2: Focus on Core Areas - The company is concentrating on critical therapeutic areas such as emergency medicine, dermatology, ophthalmology, anesthetics, respiratory, and autoimmune diseases, based on thorough research into disease patterns and clinical needs [3]. - The raw material manufacturing center achieved a capacity utilization rate of 92% this month, showcasing operational efficiency [3]. Group 3: R&D Investment and Innovation - Over the past three years, the company has invested more than 150 million yuan annually in R&D, with the R&D expense ratio expected to rise to 7.7% in 2024 [4]. - The company has developed several products in dermatology and ophthalmology, including the domestically exclusive Difluprednate eye drops set to launch in 2025, utilizing new technology for better drug penetration [4][5]. Group 4: Internationalization Strategy - The company is pursuing an "integrated development of domestic and international sales" strategy, leveraging its advantages in raw material and formulation integration to achieve resource sharing and market synergy [5][6]. - Tianjin Pharmaceutical is transitioning from "product export" to "capability export," aiming to build a global supply chain and local production capacity in countries along the Belt and Road Initiative [6]. Group 5: Compliance and Long-term Stability - Compliance is emphasized as a fundamental principle for sustainable growth, with the company implementing a comprehensive compliance management system and ensuring that all key personnel sign compliance commitments [7]. - The company maintains a competitive edge in the steroid hormone sector, with over 80% self-sufficiency in key raw materials and numerous international certifications [7][8]. Group 6: Long-term Vision - The company views the pharmaceutical industry as a marathon rather than a sprint, focusing on deep specialization in steroids and long-term innovation to solidify its development foundation [8][9].

Group 1 - The company’s subsidiary, Tianjin Pharmaceutical Co., Ltd., has received a registration certificate from the Ministry of Health of the Republic of Panama for its injectable drug, Methylprednisolone Sodium Succinate, allowing it to produce and sell the product in the Panamanian market [1][2] - The drug is a corticosteroid used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases and tumors, and shock treatment [1] - The global market sales for Methylprednisolone injectable products were reported to be $526 million in 2023 and $521 million in 2024 according to the IQVIA database [1] Group 2 - The registration of the drug is expected to create new opportunities for the company’s formulation business in the Panamanian market and further promote its international strategic layout [2] - The timeline for the drug's sales in foreign markets, market size, and subsequent expansion progress remains uncertain, influenced by external market conditions and exchange rate fluctuations [2]

证券日报网讯 11月18日晚间，津药药业发布公告称，近日，公司子公司津药和平（天津）制药有限公 司注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书（标志着可以生产并在巴拿马共和国市场 销售该产品）。 （编辑 楚丽君） ...

注射用甲泼尼龙琥珀酸钠是一种糖皮质激素类药物，主要用于抗炎治疗、免疫抑制治疗、血液疾病和肿 瘤的治疗、休克的治疗等。2024年津药和平向巴拿马共和国卫生部提出注册申请，2025年11月收到卫生 部通知，取得注册证书。根据IQVIA数据库显示，甲泼尼龙类注射剂2023年、2024年全球市场销售额分 别为5.26亿美元、5.21亿美元。 津药和平注射用甲泼尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书，将为制剂业务拓展巴拿马市场带 来新机遇，也将进一步推动公司国际化战略布局。 格隆汇11月18日丨津药药业(600488.SH)公布，公司子公司津药和平（天津）制药有限公司注射用甲泼 尼龙琥珀酸钠获得巴拿马共和国卫生部注册证书（标志着可以生产并在巴拿马共和国市场销售该产 品）。药品名称：注射用甲泼尼龙琥珀酸钠，批准文号：210124。 ...

Core Viewpoint - The company announced that its subsidiary, Tianyao Heping, has received registration certification from the Ministry of Health of the Republic of Panama for its injectable methylprednisolone sodium succinate (500mg freeze-dried powder injection), allowing for local production and sales [1] Group 1: Product Approval and Market Expansion - The approved drug is a corticosteroid used for anti-inflammatory treatments [1] - The registration application was submitted in 2024, and the certification was obtained in November 2025 [1] - The global sales figures for methylprednisolone injectable products are projected to be $526 million in 2023 and $521 million in 2024 [1] Group 2: Strategic Implications - This approval presents an opportunity for the company to expand its formulation business into the Panamanian market, enhancing its internationalization strategy [1] - However, there is uncertainty regarding the sales performance in this new market [1]

Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. (600488.SH) announced that its subsidiary, Tianjin He Ping Pharmaceutical Co., Ltd., has received registration certification from the Ministry of Health of the Republic of Panama for its injectable Methylprednisolone Sodium Succinate, allowing the product to be produced and sold in the Panamanian market [1] Group 1 - The injectable Methylprednisolone Sodium Succinate is a corticosteroid medication primarily used for anti-inflammatory treatment, immunosuppressive therapy, treatment of blood diseases, tumor treatment, and shock treatment [1]

Group 1 - National Integrated Circuit Industry Fund plans to reduce its stake in Jiangbolong by no more than 4,159,815 shares, accounting for 1.00% of the total share capital, between May 27, 2025, and August 26, 2025 [1] - The reduction is due to the fund's operational management needs and will be executed through centralized bidding at market prices [1] - The implementation of this reduction plan will not lead to a change in the company's control or significantly impact its governance structure and ongoing operations [1] Group 2 - Haitai Weiye has received approval from the China Securities Regulatory Commission for its H-share issuance, planning to issue no more than 710.52 million overseas listed ordinary shares [2] - The listing will take place on the main board of the Hong Kong Stock Exchange, but the matter still carries uncertainties [2] Group 3 - Fudan Zhangjiang announced a price reduction of at least 35% for its Doxorubicin Liposome Injection starting May 1, 2025, which is expected to negatively impact sales revenue [3] - The drug generated approximately RMB 210 million in sales for the year 2024, representing 29% of the company's total sales revenue [3] - The price adjustment may lead to a risk of single product loss for the drug in 2025 [3] Group 4 - Xinyuan Technology's director expressed inability to guarantee the authenticity and completeness of the 2024 annual report and related financial documents, citing significant issues identified by the audit firm [4] - The company has received a notice of investigation from the securities regulatory authority, and the audit report issued was unable to express an opinion [4] Group 5 - ST Xinchao announced that its stock will be suspended from trading starting May 6, 2025, due to the inability to disclose the audited 2024 annual report and the 2025 Q1 report within the legal timeframe [5] - If the company fails to disclose the 2024 annual report within two months of the suspension, it will face delisting risk warnings [5] Group 6 - Huakang Clean has pre-won a project worth RMB 167 million [6] - Tongguang Cable has pre-won a procurement project from the State Grid valued at RMB 142 million [6] - Fengmao Co. has increased its investment in a production base in Thailand to RMB 26 million [6] Group 7 - Huaren Pharmaceutical's wholly-owned subsidiary has obtained a medical device registration certificate for wound dressings [7] Group 8 - Major shareholders of Kairun Co. plan to reduce their holdings by no more than 9 million shares [10] - CITIC Securities has completed its reduction plan for China Gold [10] - The reduction plan for Hengfeng Information's director and vice president has been completed [10]

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]